Showing results (191-200 of 422) with videos related to
Sort By:
Pageof 43
Clinical Rheumatology|April 7, 2000
Filtration of cerebrospinal fluid for acute demyelinating neuropathy in systemic lupus erythematosusH D Stahl, P Kalischewski, C Orda, et al.Clinical Nuclear Medicine|November 27, 2025
First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [225Ac]Ac-DOTA-LM3Elisabetta Perrone, Shagufta Shaheen, Pamela L Kunz, et al.Archives of Disease in Childhood. Fetal and Neonatal Edition|May 15, 2009
Rapid quantitative procalcitonin measurement to diagnose nosocomial infections in newborn infantsA Jacquot, J-M Labaune, T-P Baum, et al.The International Journal of Biological Markers|October 1, 1996
Generation of human monoclonal anti-idiotypic antibodies with specificity to the murine monoclonal anti-CA 125 antibody B43.13J B Oltrogge, B Donnerstag, R P Baum, et al.Journal of the American Academy of Dermatology|January 1, 1997
Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skinJ Reichrath, S M Müller, A Kerber, et al.Hybridoma|February 1, 1997
OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cellsR Madiyalakan, R Yang, B C Schultes, et al.The International Journal of Biological Markers|January 1, 1997
How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assaysJ B Oltrogge, R P Baum, K N Lema, et al.Pneumologie (Stuttgart, Germany)|January 18, 2012
[Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system]D Hörsch, Y Sayeg, R Bonnet, et al.Cancer Immunology, Immunotherapy : CII|July 22, 1998
Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)B C Schultes, R P Baum, A Niesen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 10, 2021
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and DosimetryChristiane Schuchardt, Jingjing Zhang, Harshad R Kulkarni, et al.Pageof 43